Patients With Advanced Solid Tumors clinical trials

Study of LM-350 for advanced solid tumors

This trial tests an experimental drug called LM-350 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.

CG001419 Tablets for Advanced Solid Tumors with NTRK Changes

This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.

Study of a new drug for advanced solid tumors that haven't responded to treatment

This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.

A study of Sapu003 for advanced tumors sensitive to mTOR

This trial tests a new drug, Sapu003, in people with certain advanced cancers that may respond to mTOR-targeted therapy. It is looking at two groups: postmenopausal women with a type of breast cancer (HR+/HER2-), and adults with kidney, liver, neuroendocrine, or TSC-related tumors. The goal is to see if Sapu003 is safe and effective.

Testing a medicine injected into tumors for advanced cancers

This Phase 1 study tests IVX037, a medicine given directly into a solid tumor, to see if it is safe and may shrink tumors. It is for people with certain advanced colorectal, stomach/gastroesophageal, or ovarian cancers that have limited treatment options.

Testing LOXO-783 for PIK3CA-mutated cancers

This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.

Testing a new drug for advanced ovarian cancer

This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).

TCR-T cell therapy for AFP-positive liver and other cancers

This trial tests an experimental cell treatment called HRYZ-T102 TCR-T for people with advanced liver cancer or other solid tumors that make a protein called AFP. The treatment uses your own immune cells, modified in a lab to target and kill cancer cells.

Two-drug combo for advanced colorectal cancer

This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.

ALE.P02 for advanced squamous cell cancers with CLDN1

This trial tests a new drug called ALE.P02 for people with advanced squamous cell cancers (like lung, head and neck, esophagus, or skin cancer) that have a certain protein called CLDN1. The drug is given alone and aims to shrink or stop the cancer.

Lirafugratinib for solid tumors with FGFR2 fusion

This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.

Studying resistance to antibody-drug conjugates in advanced cancer

This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.

Testing NST-628 pills for advanced solid tumors with RAS/MAPK changes

This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.

Tested medicine for tumors with TrkA changes, alone or with pembrolizumab

This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.

New targeted pill combo for advanced colon or stomach cancers

This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.

Meaning-centered group therapy for caregiver wellbeing

This study tests whether group therapy focused on meaning and purpose can improve the wellbeing of people caring for someone with advanced cancer or another serious illness. Caregivers will join virtual group sessions and complete questionnaires about their feelings and stress.

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors

A new drug for cancers with KRAS G12D mutation

This trial tests a new drug called QTX3034 in people whose cancer has a specific genetic change called KRAS G12D. The drug aims to block the mutated protein that helps cancer grow, and may work even if other treatments have stopped working.

Testing HMBD-501 for HER3-positive advanced solid tumors

This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.

Study of CTS3497 for cancers missing a specific protein

This trial tests a new drug called CTS3497 in people whose tumors lack a protein called MTAP. The drug aims to stop cancer cells from growing by targeting a weakness caused by this missing protein.

Testing AWT020 for advanced cancers

This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.

Study tests pembrolizumab or nivolumab plus a diabetes-like drug

This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.

Testing TQB3122 capsules in advanced solid tumors

This trial tests an experimental oral capsule (TQB3122) for safety and early signs of effectiveness in people with advanced solid tumors that have not responded to standard therapies. It is for patients who are relatively healthy and have specific cancer types like ovarian, breast, or prostate cancer.

Study of TQB3205 for advanced solid tumors

This trial tests an experimental drug called TQB3205 for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how it affects the tumors.